JP2021532784A5 - - Google Patents

Info

Publication number
JP2021532784A5
JP2021532784A5 JP2021505393A JP2021505393A JP2021532784A5 JP 2021532784 A5 JP2021532784 A5 JP 2021532784A5 JP 2021505393 A JP2021505393 A JP 2021505393A JP 2021505393 A JP2021505393 A JP 2021505393A JP 2021532784 A5 JP2021532784 A5 JP 2021532784A5
Authority
JP
Japan
Prior art keywords
seq
peptide
pharmaceutically acceptable
acceptable salt
oligonucleotide complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021505393A
Other languages
English (en)
Japanese (ja)
Other versions
JP7564087B2 (ja
JP2021532784A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/043920 external-priority patent/WO2020028254A1/en
Publication of JP2021532784A publication Critical patent/JP2021532784A/ja
Publication of JP2021532784A5 publication Critical patent/JP2021532784A5/ja
Application granted granted Critical
Publication of JP7564087B2 publication Critical patent/JP7564087B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021505393A 2018-07-30 2019-07-29 アンチセンス送達のための三量体ペプチド Active JP7564087B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862711894P 2018-07-30 2018-07-30
US62/711,894 2018-07-30
PCT/US2019/043920 WO2020028254A1 (en) 2018-07-30 2019-07-29 Trimeric peptides for antisense delivery

Publications (3)

Publication Number Publication Date
JP2021532784A JP2021532784A (ja) 2021-12-02
JP2021532784A5 true JP2021532784A5 (enExample) 2022-07-29
JP7564087B2 JP7564087B2 (ja) 2024-10-08

Family

ID=69230560

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021505393A Active JP7564087B2 (ja) 2018-07-30 2019-07-29 アンチセンス送達のための三量体ペプチド

Country Status (5)

Country Link
US (2) US12168059B2 (enExample)
EP (1) EP3829597A4 (enExample)
JP (1) JP7564087B2 (enExample)
TW (1) TW202019442A (enExample)
WO (1) WO2020028254A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019165183A1 (en) 2018-02-22 2019-08-29 Entrada Therapeutics, Inc. Compositions and methods for treating mitochondrial neurogastrointestinal encephalopathy
EP3765030A4 (en) * 2018-03-16 2022-01-26 Sarepta Therapeutics, Inc. CHIMERIC PEPTIDES FOR ANTISENSE ADMINISTRATION
WO2019217682A1 (en) 2018-05-09 2019-11-14 Ohio State Innovation Foundation Cyclic cell-penetrating peptides with one or more hydrophobic residues
US20250228954A1 (en) * 2020-01-24 2025-07-17 Sarepta Therapeutics, Inc. Designing Antisense Oligonucleotide Delivery Peptides by Interpretable Machine Learning
US20250051393A1 (en) * 2021-05-10 2025-02-13 Entrada Therapeutics, Inc. Compositions and methods for modulating interferon regulatory factor-5 (irf-5) activity
IL308353A (en) * 2021-05-10 2024-01-01 Entrada Therapeutics Inc Compositions and methods for modulating tissue distribution of intracellular therapies
JP2024518476A (ja) * 2021-05-10 2024-05-01 エントラーダ セラピューティクス，インコーポレイティド ｍＲＮＡスプライシングを調節するための組成物及び方法
KR20240037299A (ko) * 2021-07-23 2024-03-21 빔 테라퓨틱스, 인크. Crispr/cas 편집 시스템용 가이드 rna
WO2023191953A1 (en) 2022-03-26 2023-10-05 University Of Rhode Island Board Of Trustees Pnictogen-containing heterocyclic compounds and their use
WO2023192510A1 (en) * 2022-03-31 2023-10-05 Entrada Therapeutics, Inc. β-CATENIN ANTIBODIES
WO2026080471A2 (en) 2024-10-07 2026-04-16 Flagship Pioneering Innovations Vi, Llc Compositions of trem conjugates and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9161948B2 (en) * 2011-05-05 2015-10-20 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
AU2011367230B2 (en) 2011-05-05 2017-08-10 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
WO2015069665A1 (en) * 2013-11-06 2015-05-14 Rain Bioscience, Inc. Intracellular delivery system for oligomers having low renal clearance rate
KR102644053B1 (ko) 2015-05-19 2024-03-06 사렙타 쎄러퓨틱스 인코퍼레이티드 펩티드 올리고뉴클레오티드 콘주게이트

Similar Documents

Publication Publication Date Title
US10793605B2 (en) Conformationally-preorganized, miniPEG-containing γ-peptide nucleic acids
CN101547932B (zh) 核苷芳基氨基磷酸酯及其作为抗病毒制剂处理丙型肝炎病毒的应用
FI120261B (fi) PNA-synteesi käyttämällä heikkojen happojen suhteen labiilia aminonsuojaryhmää
JP2018530560A5 (enExample)
JP2022546609A5 (enExample)
JP2020537654A5 (enExample)
JP2021518361A5 (enExample)
JPH0753753B2 (ja) タチキニン由来の新規ぺプチドおよび医薬組成物
JP2022539091A5 (enExample)
JP2025513521A5 (enExample)
US6713602B1 (en) Synthetic procedures for peptide nucleic acids
AU2024265463A1 (en) Preparation of peptide inhibitor of interleukin-23 receptor and use thereof
De Cola et al. Carboxyalkyl peptoid PNAs: synthesis and hybridization properties
ITMI951450A1 (it) Esteri acilici di amminoacidi achirali di gangiclovir e relativi derivati
SK2793A3 (en) Polypeptide compounds with ability release of growth hormone
JP2021515005A5 (enExample)
JP2024537711A5 (enExample)
HUE028918T2 (en) Effective peptide couplings and their use in the synthesis and isolation of cyclopenta (G) quinazoline trinodium salt
JPWO2023127752A5 (enExample)
AU2022291626A1 (en) Improved process for preparing imetelstat
JP2020537652A5 (enExample)
US7038037B2 (en) Method for sequential support-bound synthesis of conjugated oligomeric compounds
US9017673B2 (en) Peptide analogues comprising at least one type of aminoacylaza-$g(b)<sp>3</sp>and the use thereof, in particular for therapy
KR20230109301A (ko) 신규한 pna 단량체 및 이를 포함하는 pna 올리고머
Ciapetti et al. Design and synthesis of chiral peptidic nucleic acids